Literature DB >> 31174938

Integration of needle-free jet injection with advanced electroporation delivery enhances the magnitude, kinetics, and persistence of engineered DNA vaccine induced immune responses.

Jingjing Jiang1, Stephanie J Ramos2, Preeti Bangalore1, Paul Fisher1, Kristine Germar1, Brian K Lee1, Dan Williamson1, Andrea Kemme1, Eric Schade1, Jay McCoy1, Kar Muthumani3, David B Weiner3, Laurent M Humeau1, Kate E Broderick1.   

Abstract

The combination of optimized DNA constructs, improved formulations and advanced in vivo electroporation (EP) has been shown to generate potent and efficacious immune responses in the clinic. Needle-free jet injection has also been reported to improve DNA vaccine delivery over standard needle and syringe in clinical trials. Here we investigated the impact of combined jet injection and EP (Jet-EP) delivery on muscle transfection efficiency and DNA vaccine immunogenicity in rabbits and nonhuman primates (NHPs) compared to jet injection alone. Our results show that the addition of EP significantly enhanced in vivo DNA transfection efficiency of rabbit muscle over jet injection alone. Jet-EP delivery augmented the rate and magnitude of DNA vaccine induced humoral and cellular responses over jet injection alone in both rabbits and NHPs. Jet-EP delivery also resulted in higher proportions of polyfunctional antigen specific T cells producing IFNγ, IL-2, and/or TNFα. Elevated antibody levels were sustained nine months post immunization in NHPs immunized with a DNA vaccine using Jet-EP delivery, far outperforming jet delivery alone. Our results provide proof-of-concept that addition of advanced EP to needle-free jet injection delivery improves in vivo DNA transfection efficiency, increasing the magnitude, rate and duration of cellular and humoral immune responses to DNA vaccines. This combination likely has significant advantages in important vaccine and immunotherapy settings.
Copyright © 2019 Inovio Pharmaceuticals Inc. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  DNA vaccine; Electroporation; Immunogenicity; Needle-free injection

Mesh:

Substances:

Year:  2019        PMID: 31174938     DOI: 10.1016/j.vaccine.2019.05.054

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  2 in total

1.  Multivalent DNA Vaccines as A Strategy to Combat Multiple Concurrent Epidemics: Mosquito-Borne and Hemorrhagic Fever Viruses.

Authors:  Jingjing Jiang; Stephanie J Ramos; Preeti Bangalore; Dustin Elwood; Kathleen A Cashman; Sagar B Kudchodkar; Katherine Schultheis; Holly Pugh; Jewell Walters; Jared Tur; Jian Yan; Ami Patel; Kar Muthumani; Connie S Schmaljohn; David B Weiner; Laurent M Humeau; Kate E Broderick
Journal:  Viruses       Date:  2021-02-27       Impact factor: 5.048

2.  DNA Based Vaccine Expressing SARS-CoV-2 Spike-CD40L Fusion Protein Confers Protection Against Challenge in a Syrian Hamster Model.

Authors:  Levi A Tamming; Diana Duque; Anh Tran; Wanyue Zhang; Annabelle Pfeifle; Emmanuel Laryea; Jianguo Wu; Sathya N Thulasi Raman; Caroline Gravel; Marsha S Russell; Anwar M Hashem; Reem M Alsulaiman; Rowa Y Alhabbab; Jun Gao; David Safronetz; Jingxin Cao; Lisheng Wang; Wangxue Chen; Michael J W Johnston; Simon Sauve; Michael Rosu-Myles; Xuguang Li
Journal:  Front Immunol       Date:  2022-01-12       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.